Dr. Howard has served as a director since September 2016 and as Chairman of the Board since February 2017. He has been a Senior Managing Director of Hudson Ventures since 1996. After practicing medicine from 1981 to 1988, he co-founded Presstek, Inc., a publicly-held graphic arts technology company whose market value grew from $12 million to over $800 million under his direction. Dr. Howard served as President and CEO of Presstek from 1987 until 1992, and served on the Presstek Board of Directors for over twenty years. He was a Clinical Professor in the Department of Psychiatry at the Morsani College of Medicine at the University of South Florida, and the Entrepreneur-in-Residence and an Adjunct Professor at the University of South Florida Center for Entrepreneurship. In addition, Dr. Howard has worked since 2012 as a consultant to The Villages, the largest retirement community in the U.S., assisting them in building a “state of the art” healthcare delivery system. Dr. Howard currently serves as Chairman of the Board of Directors of iCAD, inc., also a publicly-held company, and the University of New Hampshire Foundation Board of Trustees. He holds a B.Sc. degree from the University of New Hampshire and an M.D. degree from New York Medical College.
Dr. Haluska has served as BioCancell’s CEO since October 2016 and as a director since December 2016. He most recently served as Chief Medical Officer and Senior Vice President of Clinical R&D at ARIAD Pharmaceuticals, Inc., where he held overall responsibility for clinical development strategy. At ARIAD he led the clinical development and approval of ponatinib (marketed as Iclusig) in the US, EU and other territories, as well as the development of brigatinib, which has been submitted for FDA review.
Dr. Haluska graduated from Harvard College and the University of Pennsylvania School of Medicine, undertook medical training at Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI), and a fellowship at the Massachusetts Institute of Technology Center for Cancer Research. He became assistant professor of medicine at Harvard Medical School, and leader of the melanoma research programs at the MGH Cancer Center and the DFCI through the Dana-Farber Harvard Cancer Center. Subsequently he was deputy director of the Tufts New England Medical Center Cancer Center. He has also served as a flight surgeon in the U.S. Air Force and continues to serve in the Massachusetts Air National Guard with the rank of Colonel.
Mr. Goldberg has served as a director since March 2011. He is a Vice President at Clal Biotechnology Industries (TASE: CBI), leading CBI’s strategic investment decisions and technological development. Mr. Goldberg is also the managing director of Anatomy Medical Technology fund, CBI’s medical device investment arm.
Mr. Goldberg serves as executive chairman and board member of several biomedical companies. He holds an M.A. in Economics and Finance from Tel Aviv University and a B.Sc. in Physics and Mathematics from the Hebrew University of Jerusalem.
Mr. Hardy is the co-founder and CEO of Brickell Biotech, Inc., a pharmaceutical company focused on developing novel drugs for the treatment of skin diseases. Prior to Brickell, he was the co-founder and President of Concordia Pharmaceuticals, Inc. an oncology drug development company acquired by Kadmon Corporation in 2011. From 1992 to 1998, he was President of SANO Corporation, a pharmaceutical company that he co-founded, focused on the development of novel transdermal drug delivery systems that was acquired by Elan Corporation in 1998. Prior to SANO, Mr. Hardy held various corporate roles with IVAX Corporation, Key Pharmaceuticals, and Hoechst-Roussel Pharmaceuticals, Inc. He earned his B.S. degree in Pharmacy from the University of North Carolina – Chapel Hill and M.B.A. from UNC – Greensboro.
Mr. Kohlberg has served as a director since February 2017. He is the Senior Associate Provost and Chief Technology Development Officer of Harvard University. Previously, he was CEO of the Tel Aviv University Economic Corporation and CEO of RAMOT at Tel Aviv University. He served as Vice President at New York University Medical Center and Vice Provost of New York University. He also served as the Managing Director of Yeda R&D Company of the Weizmann Institute of Science.
Mr. Kohlberg received his M.B.A. from INSEAD and LL.B. from Tel Aviv University.
Mr. Schlachet has served as a director since January 2010. He was previously CEO of Syneron Medical Ltd., Managing Partner of Biocom (a venture capital fund specializing in the life sciences area), senior VP and CFO of Strauss Elite Holdings, VP Finance & Administration of the Weizmann Institute of Science, and CEO of the Weizmann Institute’s technology transfer company, Yeda R&D Co. Ltd. Mr. Schlachet holds a B.Sc. in chemical engineering from the Technion, and an MBA (Finance) from the Tel Aviv University.
Prof. Shalit is the CEO of the Galilee Biomedical Research Administration. He previously served as the Director of the Pediatric Infectious Disease Unit at Schneider Children’s Medical Center in Petach Tikva, Israel, and was Director-General of both the Schneider Children’s and Carmel Medical Centers. He has received a Certificate of Appreciation from the World Health Organization for outstanding efforts and success in eradicating poliomyelitis in Israel. Prof. Shalit holds an MD from the Sackler School of Medicine, Tel-Aviv University and a MPA (Master in Public Administration) from the Kennedy School of Government at Harvard University.
Mr. Veru has been the Chief Investment Officer (Institutional) of Palisade Capital Management, an asset manager with $3 billion under management, since 2000, with oversight responsibilities for all of Palisade’s investment strategies that trade publicly-traded securities. Mr. Veru previously held a variety of analytical positions at Drexel Burnham Lambert and later at Smith Barney. From 1992 through 1999, Mr. Veru was the President and Director of Research at Awad Asset Management and helped oversee the firm’s growth from start up to more than $1 billion of small-cap institutional and high net worth assets. Prior to Awad, Mr. Veru held a variety of analytical roles at Drexel Burnham Lambert and later at Smith Barney Harris Upham. In addition to his professional responsibilities, Mr. Veru is a member of the Board of Overseers of the St. Lukes and Roosevelt hospital, a member of the finance committee of the Dwight-Englewood School, and a member of the Board of the McCarton School for autistic children. He is a frequent guest on CNBC, Bloomberg News, Fox News and CNN, and also contributes market opinions to various financial publications. Mr. Veru holds a B.A. in Government from Franklin & Marshall College.